Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
F520 in Relapsed/Refractory Peripheral T-Cell Lymphoma
CTR20201523Phase 2Terminated
- Sponsor
- Shandong New Era Pharmaceutical
- Start
- Aug 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of rulonilimab in peripheral T-cell lymphoma (PTCL), sponsored by Shandong New Era Pharmaceutical. Started Aug 2020; status: terminated.
02
Drugs
rulonilimab
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on CTR20201523.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20201523.